Corvus Pharmaceuticals (CRVS) Net Cash Flow (2015 - 2026)

Corvus Pharmaceuticals' Net Cash Flow history runs 12 years deep, the most recent figure standing at $35.5 million for Q1 2026.

• In Q1 2026, Net Cash Flow rose 1049.64% year-over-year to $35.5 million; the TTM figure through Mar 2026 stood at $35.1 million (up 206.93% YoY), while the FY2025 annual figure was -$4.2 million, down 7.32% from the prior year.
• Net Cash Flow for Q1 2026 stood at $35.5 million, up from $1.7 million in the prior quarter.
• The five-year high for Net Cash Flow was $35.5 million in Q1 2026, with the low at -$32.0 million in Q1 2022.
• The 5-year median for Net Cash Flow is -$3.7 million (2025), against an average of -$3.2 million.
• The sharpest annual moves came in 2024 and 2026: Net Cash Flow slumped 1051.55% in 2024, then surged 1049.64% in 2026.
• Corvus Pharmaceuticals' Net Cash Flow stood at -$11.4 million in 2022, then soared by 34.51% to -$7.5 million in 2023, then soared by 154.24% to $4.1 million in 2024, then slumped by 57.91% to $1.7 million in 2025, then jumped by 1978.76% to $35.5 million in 2026.
• Business Quant data shows CRVS's Net Cash Flow at $35.5 million in Q1 2026, $1.7 million in Q4 2025, and -$11.8 million in Q3 2025.